William Soliman, PhD

As timelines change, medical affairs teams must adjust their skillsets.

Efforts to regulate pharma prices will impact other sectors of healthcare, with PBMs likely to feel the impact.

The current administration’s efforts are just the latest attempt from the government to improve drug prices in the US.

Multiple pharma companies have already announced plans to invest in domestic projects.

As drug prices in the US fluctuate, pharma companies may look to other regions for opportunity.

Pharma companies have the choice of facing strict tariffs or negotiating with the current administration.

A look at the rise of prior authorization certified specialists (PACS)—and their value in improving patient access and outcomes.

A focus on medical affairs and medical science liaisons.